The successful synthesis of complex pharmaceutical compounds like Brigatinib hinges on the precise specifications of the chemical intermediates used. 1-Methyl-4-(Piperidin-4-yl)-Piperazine (CAS 53617-36-0) is a pivotal intermediate in this process, and understanding its key specifications is vital for quality assurance and consistent production. These specifications dictate the compound's suitability for pharmaceutical applications and its reliability in complex chemical reactions.

Primary among these specifications is purity. For 1-Methyl-4-(Piperidin-4-yl)-Piperazine, a purity of ≥98.0% is typically required. This high level of purity is essential to minimize side reactions and ensure that the final drug product meets stringent regulatory standards. Total impurity levels are usually kept below 2%, with individual impurities not exceeding 0.5%. Such strict controls are standard practice for reputable 1-Methyl-4-(Piperidin-4-yl)-Piperazine manufacturers, including NINGBO INNO PHARMCHEM CO.,LTD., who understand the sensitive nature of pharmaceutical synthesis.

Beyond purity, other critical specifications include the physical appearance, which is commonly described as an off-white to gray solid. The molecular formula (C10H21N3) and molecular weight (183.294 g/mol) are fundamental identifiers that confirm the identity and composition of the intermediate. Thermal properties, such as the melting point (53-56°C) and boiling point (260.9±8.0 °C at 760 mmHg), also provide important information for process design and handling. These details collectively define the quality profile of 1-Methyl-4-(Piperidin-4-yl)-Piperazine.

For pharmaceutical companies looking to purchase 1-Methyl-4-(Piperidin-4-yl)-Piperazine, partnering with reliable suppliers in China like NINGBO INNO PHARMCHEM CO.,LTD. ensures access to intermediates that consistently meet these exacting standards. This meticulous attention to specifications is what underpins the development and production of effective targeted therapies, ultimately benefiting patient health. The careful selection and verification of chemical intermediates are therefore non-negotiable aspects of pharmaceutical manufacturing.